| Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio LF Pippa, ML de Oliveira, A Rocha, JM de Andrade, VL Lanchote Journal of pharmaceutical and biomedical analysis 185, 113231, 2020 | 25 | 2020 |
| Systemic lupus erythematosus activity affects the sinusoidal uptake transporter OATP1B1 evaluated by the pharmacokinetics of atorvastatin RN Cestari, RDR de Oliveira, FFL de Souza, LF Pippa, GHB Nardotto, ... Clinical and Translational Science 13 (6), 1227-1235, 2020 | 12 | 2020 |
| Pharmacokinetics of carboplatin in combination with low-dose cyclophosphamide in female dogs with mammary carcinoma MC Machado, PA Yamamoto, LF Pippa, NV de Moraes, FMF Neves, ... Animals 12 (22), 3109, 2022 | 10 | 2022 |
| Sensitive LC-MS/MS methods for amphotericin B analysis in cerebrospinal fluid, plasma, plasma ultrafiltrate, and urine: application to clinical pharmacokinetics LF Pippa, MP Marques, ACT Silva, FC Vilar, TM de Haes, BAL Fonseca, ... Frontiers in Chemistry 9, 782131, 2021 | 9 | 2021 |
| Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients … ML de Oliveira, A Rocha, GHB Nardotto, LF Pippa, BP Simoes, ... Journal of Pharmaceutical and Biomedical Analysis 191, 113576, 2020 | 7 | 2020 |
| Clinical treatment for hepatitis C reverses CYP2C19 inhibition LF Pippa, CP Vieira, JA Caris, A Rocha, CP Garcia, REF Rezende, ... British Journal of Clinical Pharmacology 87 (10), 4013-4019, 2021 | 5 | 2021 |
| Effect of Chronic Hepatitis C on the Activity of the Membrane Transporters P‐gp and OATP1B1/BCRP on Patients With Different Stages of Hepatic Fibrosis LF Pippa, CP Vieira, JA Caris, A Rocha, MP Marques, CP Garcia, ... Clinical Pharmacology & Therapeutics 114 (1), 173-181, 2023 | 3 | 2023 |
| Impact of obesity and roux-en-Y gastric bypass on the pharmacokinetics of (R)- and (S)-omeprazole and intragastric pH LF Pippa, V Vozmediano, L Mitrov-Winkelmolen, D Touw, A Soliman, ... CPT: Pharmacometrics & Systems Pharmacology, 1-14, 2024 | 1 | 2024 |
| Simulating (R)-omeprazole & (S)-omeprazole Pharmacokinetics in Obese & Post-bariatric Surgery Patients By Physiologically-based Pharmacokinetic Modeling L Pippa, P Yamamoto, R Cristofoletti, V Vozmediano Esteban, ... 2023 American College of Clinical Pharmacology (ACCP) Annual Meeting, 78-79, 2023 | | 2023 |
| Mitigation of rocuronium induced residual neuromuscular blockade risk by means of a population PK/PD model M Happ, L Pippa, G Lauretti, A Gebhart, G Weindl, F Azeredo, ... 14th American Conference on Pharmacometrics (ACoP), 170, 2023 | | 2023 |
| Suppression of CYP isoforms in patients with chronic hepatitis C before and after pharmacological treatment depends on the stage of hepatic fibrosis L Pippa, C Vieira, J Caris, A Rocha, C Garcia, R Rezende, V Lanchote The Liver Meeting American Association for the Study of Liver Diseases …, 2021 | | 2021 |
| O tratamento farmacológico para hepatite C crônica reverte a inibição de CYP2C19 LF Pippa, CP Vieira, JA Caris, A Rocha, CP Garcia, REF Rezende, ... XXVI Congresso Brasileiro de Hepatologia (Hepato2021), 105-106, 2021 | | 2021 |
| Disease-Drug Interactions in Chronic Hepatitis C: Suppression of CYP3A & P-gp/OATP in Patients With Different Stages of Hepatic Fibrosis LF Pippa, CP Vieira, JA Caris, A Rocha, MPM Pereria, CP Garcia, ... 2021 American College of Clinical Pharmacology (ACCP) Annual Meeting, 101, 2021 | | 2021 |
| Hepatitis C virus infection treatment reverses CYP2C19 inhibition using omeprazole as a probe drug in patients with hepatic fibrosis L Pippa, C Vieira, J Caris, A Rocha, R Rezende, V Lanchote American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2021 …, 2021 | | 2021 |
